Ritonavir nanosuspensions prepared by microfluidization with enhanced solubility and desirable immunological properties

References

• Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. 2015. Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 478(2):540–552.
   PubMed Web of Science ®Google Scholar
• Aslam S, Jahan N, Ur Rehman K, Asi MR. 2020. Development of sodium lauryl sulphate stabilized nanosuspension of Coriandrum sativum to enhance its oral bioavailability. J Drug Deliv Sci Technol. 60:101957.
   Web of Science ®Google Scholar
• Baek IH, Kim JS, Ha ES, Choo GH, Cho W, Hwang SJ, Kim MS. 2014. Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose. Int J Biol Macromol. 67:53–57.
   PubMed Web of Science ®Google Scholar
• Campardelli R, Reverchon E. 2015. α-Tocopherol nanosuspensions produced using a supercritical assisted process. J Food Eng. 149:131–136.
   Web of Science ®Google Scholar
• Chogale M, Gite S, Patravale V. 2020. Comparison of media milling and microfluidization methods for engineering of nanocrystals: a case study. Drug Dev Ind Pharm. 46(11):1763–1775.
   PubMed Web of Science ®Google Scholar
• De Espíndola B, Beringhs AO, Sonaglio D, Stulzer HK, Silva MAS, Ferraz HG, Pezzini BR. 2019. Liquisolid pellets: a pharmaceutical technology strategy to improve the dissolution rate of ritonavir. Saudi Pharm J. 27(5):702–712.
   PubMed Web of Science ®Google Scholar
• Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergström CAS. 2010. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm. 7(5):1419–1430.
   PubMedGoogle Scholar
• Grau MJ, Kayser O, Müller RH. 2000. Nanosuspensions of poorly soluble drugs – reproducibility of small scale production. Int J Pharm. 196(2):155–159.
   PubMed Web of Science ®Google Scholar
• Hatahet T, Morille M, Hommoss A, Dorandeu C, Müller RH, Bégu S. 2016. Dermal quercetin SmartCrystals®: formulation development, antioxidant activity and cellular safety. Eur J Pharm Biopharm. 102:51–63.
   PubMed Web of Science ®Google Scholar
• Hernández-Trejo N, Kayser O, Steckel H, Müller RH. 2005. Characterization of nebulized buparvaquone nanosuspensions – effect of nebulization technology. J Drug Target. 13(8–9):499–507.
   PubMed Web of Science ®Google Scholar
• Ilevbare GA, Liu H, Edgar KJ, Taylor LS. 2012. Understanding polymer properties important for crystal growth inhibition-impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des. 12(6):3133–3143.
   Web of Science ®Google Scholar
• Ivanova EA, Orekhov AN. 2015. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview. Biomed Res Int. 2015:327470.
   PubMed Web of Science ®Google Scholar
• Jitta SR, Salwa, Bhaskaran NA, Marques SM, Kumar L. 2022. Recent advances in nanoformulation development of ritonavir, a key protease inhibitor used in the treatment of HIV-AIDS. Expert Opin Drug Deliv. 19(9):1133–1148.
   PubMed Web of Science ®Google Scholar
• Karakucuk A, Celebi N, Teksin ZS. 2016. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A design of experiment approach. Eur J Pharm Sci. 95:111–121.
   PubMed Web of Science ®Google Scholar
• Karakucuk A, Celebi N. 2020. Investigation of formulation and process parameters of wet media milling method to develop etodolac nanosuspensions. Pharm Res. 37(6):1–18.
   Web of Science ®Google Scholar
• Karakucuk A, Teksin ZS, Eroglu H, Celebi N. 2019. Evaluation of improved oral bioavailability of ritonavir nanosuspension. Eur J Pharm Sci. 131(February):153–158.
   PubMedGoogle Scholar
• Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. 2007. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 340(1–2):126–133.
   PubMedGoogle Scholar
• Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59(7):631–644.
   PubMed Web of Science ®Google Scholar
• Kumar S, Narayan R, Ahammed V, Nayak Y, Naha A, Nayak UY. 2018. Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. J Drug Deliv Sci Technol. 44:181–189.
   Web of Science ®Google Scholar
• Long J, Song J, Zhang X, Deng M, Xie L, Zhang L, Li X. 2020. Tea saponins as natural stabilizers for the production of hesperidin nanosuspensions. Int J Pharm. 583(May):119406.
   PubMedGoogle Scholar
• Lu Y, Wang ZH, Li T, McNally H, Park K, Sturek M. 2014. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. J Control Release. 176:76–85.
   PubMed Web of Science ®Google Scholar
• Mahesh KV, Singh SK, Gulati M. 2014. A comparative study of top-down and bottom-up approaches for the preparation of nanosuspensions of glipizide. Powder Technol. 256:436–449.
   Web of Science ®Google Scholar
• Manca ML, Lai F, Pireddu R, Valenti D, Schlich M, Pini E, Ailuno G, Fadda AM, Sinico C. 2020. Impact of nanosizing on dermal delivery and antioxidant activity of quercetin nanocrystals. J Drug Deliv Sci Technol. 55:101482.
   Web of Science ®Google Scholar
• Morris DL, Komocsar WJ. 1997. Immunophenotyping analysis of peripheral blood, splenic, and thymic lymphocytes in male and female rats. J Pharmacol Toxicol Methods. 37(1):37–46.
   PubMed Web of Science ®Google Scholar
• Möschwitzer J, Achleitner G, Pomper H, Müller RH. 2004. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 58(3):615–619.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C. 2002. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm. 237(1–2):151–161.
   PubMed Web of Science ®Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. 2014. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 35(10):3365–3383.
   PubMed Web of Science ®Google Scholar
• Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE. 2011. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 150(2):204–211.
   PubMed Web of Science ®Google Scholar
• Oktay AN, Ilbasmis-Tamer S, Han S, Uludag O, Celebi N. 2020. Preparation and in vitro/in vivo evaluation of flurbiprofen nanosuspension-based gel for dermal application. Eur J Pharm Sci. 155(September):105548.
   PubMedGoogle Scholar
• Pandey NK, Singh SK, Gulati M, Kumar B, Kapoor B, Ghosh D, Kumar R, Khursheed R, Awasthi A, Kuppusamy G, et al. 2020. Overcoming the dissolution rate, gastrointestinal permeability and oral bioavailability of glimepiride and simvastatin co-delivered in the form of nanosuspension and solid self-nanoemulsifying drug delivery system: a comparative study. J Drug Deliv Sci Technol. 60(August):102083.
   Google Scholar
• Patel AA, Patel RJ, Mishra P. 2021. Nanosuspension for oral delivery of tadalafil: pharmacodynamic and pharmacokinetic studies. J Drug Deliv Sci Technol. 61:102203.
   Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. 2010. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 56(7):827–840.
   Web of Science ®Google Scholar
• Prakash S, Vidyadhara S, Sasidhar RLC, Abhijit D, Akhilesh D. 2012. Formulation and evaluation of ritonavir nanosuspension and capsules. Inventi Impact: NDDS. 2:120–123.
   Google Scholar
• Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 3(9):785–796.
   PubMed Web of Science ®Google Scholar
• Raphael I, Nalawade S, Eagar TN, Forsthuber TG. 2015. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 74(1):5–17.
   PubMed Web of Science ®Google Scholar
• Romero GB, Keck CM, Müller RH. 2016. Simple low-cost miniaturization approach for pharmaceutical nanocrystals production. Int J Pharm. 501(1–2):236–244.
   PubMedGoogle Scholar
• Setianto AB, Nugraha YP, Suendo V, Ainurofiq A, Uekusa H, Soewandhi SN. 2020. X-ray diffraction and vibrational spectroscopic studies of the intermolecular interactions on the grinding and compaction behaviours of lopinavir and ritonavir crystals. Acta Pol Pharm Drug Res. 77(2):259–269.
   Web of Science ®Google Scholar
• Shekhawat P, Pokharkar V. 2019. Risk assessment and QbD based optimization of an eprosartan mesylate nanosuspension: in-vitro characterization, PAMPA and in-vivo assessment. Int J Pharm. 567(June):118415.
   PubMedGoogle Scholar
• Sheng Y, Zhang S, Ling J, Hu C, Zhang Z, Lv H. 2022. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome. Pharm Dev Technol. 27(4):459–468.
   PubMed Web of Science ®Google Scholar
• Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. 2010. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm. 402(1–2):213–220.
   PubMed Web of Science ®Google Scholar
• Singh SK, Srinivasan KK, Gowthamarajan K, Singare DS, Prakash D, Gaikwad NB. 2011. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm. 78(3):441–446.
   PubMed Web of Science ®Google Scholar
• Taymouri S, Ahmadi Z, Mirian M, Tavakoli N. 2021. Simvastatin nanosuspensions prepared using a combination of pH-sensitive and timed-release approaches for potential treatment of colorectal cancer. Pharm Dev Technol. 26(3):335–348.
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Junyaprasert VB, Souto EB, Müller RH. 2008. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm. 354(1–2):227–234.
   PubMed Web of Science ®Google Scholar
• Torres B, Rallón NI, Loncá M, Díaz A, Alós L, Martínez E, Cruceta A, Arnaiz JA, Leal L, Lucero C, et al. 2014. Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial. AIDS Res Hum Retroviruses. 30(5):425–433.
   PubMed Web of Science ®Google Scholar
• Tsoukas C, Gilbert L, Lewis T, Hatzakis G, Falcon R, Mrus J. 2013. Improvements in immune function and activation with 48-week darunavir/ritonavir-based therapy: GRACE substudy. ISRN AIDS. 2013:1–10.
   Google Scholar
• Van Eerdenbrugh B, Stuyven B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. 2009. Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS PharmSciTech. 10(1):44–53.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Vercruysse S, Martens Johan AMJ, Vermant J, Froyen L, Van Humbeeck J, Van den Mooter G, Augustijns P. 2008. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions – a case study with itraconazole. Eur J Pharm Biopharm. 70(2):590–596.
   PubMed Web of Science ®Google Scholar
• Wang C, Rosbottom I, Turner TD, Laing S, Maloney AGP, Sheikh AY, Docherty R, Yin Q, Roberts KJ. 2021. Molecular, solid-state and surface structures of the conformational polymorphic forms of ritonavir in relation to their physicochemical properties. Pharm Res. 38(6):971–990.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Y, Zhao J, Li C, Zhou Y, Du J, Wang Y. 2017. In vitro and in vivo evaluation of targeting tumor with folate-based amphiphilic multifunctional stabilizer for resveratrol nanosuspensions. Colloids Surf B Biointerfaces. 160:462–472.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. 2013. Stability of nanosuspensions in drug delivery. J Control Release. 172(3):1126–1141.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. 2012. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 17(1–2):71–80.
   PubMed Web of Science ®Google Scholar
• Yousaf SS, Isreb A, Khan I, Mewsiga E, Elhissi A, Ahmed W, Alhnan MA. 2021. Impact of nanosizing on the formation and characteristics of polymethacrylate films: micro- versus nano-suspensions. Pharm Dev Technol. 26(7):729–739.
   PubMed Web of Science ®Google Scholar
• Zhang D, Tan T, Gao L, Zhao W, Wang P. 2007. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm. 33(5):569–575.
   PubMed Web of Science ®Google Scholar